Olaris Announces Findings from Exploratory Analysis of Biomarkers that Predict Patient Responsiveness to Trastuzumab Therapy

Olaris’ metabolite profiling platform and machine learning algorithms have the potential to accurately indicate whether HER2-positive metastatic breast cancer patients will respond to trastuzumab therapy.

Olaris, Inc

35 Gatehouse Drive

Waltham, Massachusetts

02451

e: info@olarisBoR.com

  • Grey LinkedIn Icon
  • Grey Facebook Icon
  • Twitter

© 2021 Olaris, Inc